[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-disease":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,56,80,116,141,169,194,219,245,270,295,321,342,374,402,428,446,470,490,515],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100549078","phase-4-international-care-bundle-evaluation-in-cerebral-hemorrhage-research-100549078",false,"NCT06429332","International Care Bundle Evaluation in Cerebral Hemorrhage Research","International Care Bundle Evaluation in Cerebral Hemorrhage Research - a Batched Parallel Cluster-randomized Trial With a Baseline Period","I-CATCHER","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Non-contrast computerized tomography (NCCT) imaging-verified diagnosis of spontaneous intracerebral haemorrhage\n* ≤24 hours from symptom onset or presumed symptom onset (last seen well)\n\nExclusion Criteria:\n\n* Previous care limitation\n* End-stage comorbidity with short life-expectancy (\\\u003C6 m; e.g. terminal cancer)\n* ICH caused by brain tumor or cerebral venous thrombosis\n* Clinical signs of brain herniation at first presentation (unresponsive patient with bilaterally fixed, maximally dilated pupils)\n* Pregnant women beyond 22 weeks gestation may only be included after thorough discussion with an obstetrician to determine risks vs benefit.","ALL","18 Years",{"count":20,"type":21},3500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.",[27,28,29,30,31],"Intracerebral Hemorrhage","Intracerebral Haemorrhage","Intraventricular Hemorrhage","Stroke","Cerebrovascular Disease",[33,34,35,36,37,38,39,40,41,42],"intracerebral hemorrhage","oral anticoagulant","blood pressure lowering","early intensive blood pressure lowering","care bundle","implementation study","reversal treatment","outcome","UW-mRS","Modified Rankin Scale","RECRUITING","2026-05-20",{"date":46,"type":47},"2026-05-22","ACTUAL",{"date":49,"type":47},"2025-01-07",{"date":51,"type":21},"2027-07",{"name":53,"class":54},"Region Skane","OTHER",54,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100634773","transradial-vs-transfemoral-group-randomized-efficacy-and-safety-trial-for-cerebral-angiography-100634773","NCT07544043","Transradial vs Transfemoral Group-Randomized Efficacy and Safety Trial for Cerebral Angiography","Transradial vs Transfemoral Group-Randomized Efficacy and Safety Trial for Cerebral Angiography：A Prospective, Multicenter, Cluster-Randomized Controlled, Open-Label, Blinded Endpoint Evaluation Study（TARGET-CA）","TARGET-CA","Inclusion Criteria:\n\n1. Age \\> 18 years;\n2. Patients requiring full cerebrovascular angiography;\n3. Objective evidence indicates the patient is suitable for transfemoral or transradial cerebrovascular angiography, with upper limb vascular ultrasound 4.showing a radial artery internal diameter ≥ 1.5 mm;\n\n5.Modified Rankin Scale (mRS) score ≤ 2 points; 6.Signed informed consent form.\n\nExclusion Criteria:\n\n1. Positive right Allen's test\u002FBarbeau test; femoral artery occlusion (for the TFA group);\n2. Local infection or trauma at the puncture site;\n3. Coagulation abnormalities: INR \\> 1.5 or platelet count \\\u003C 50 × 10⁹\u002FL;\n4. Presence of access vessel disease or anatomical variation deemed potentially hazardous to the subject, such as aortic arch interruption, subclavian artery occlusion, or aortic dissection;\n5. Pregnancy;\n6. Planned or recent (within the past 2 weeks) major surgery or severe trauma;\n7. Expected survival less than 5 years;\n8. Severe cardiac, hepatic, renal, or other organ dysfunction;\n9. Contraindication to contrast agents used in cerebrovascular angiography;\n10. Inability to comply with follow-up.",{"count":65,"type":21},2473,[67],"NA","This study will compare the efficacy and safety of the transradial approach versus the transfemoral approach for performing full cerebral angiography. Participants will undergo cerebral angiography via one of the two approaches and will be followed up during and after the procedure. The primary endpoint of this study is to evaluate the success rate of completing full cerebral angiography (including superselective catheterization of bilateral common carotid arteries, subclavian arteries near the vertebral artery origin, and the aortic arch) via the transradial approach versus the transfemoral approach. During the study, the medical team will also document procedural details, incidence of complications, patient comfort, and related costs to comprehensively evaluate the clinical performance differences between the two approaches.",[31],"NOT_YET_RECRUITING","2026-04-19",{"date":73,"type":47},"2026-04-22",{"date":75,"type":21},"2026-05-01",{"date":77,"type":21},"2027-05-01",{"name":79,"class":54},"Gansu Provincial Maternal and Child Health Care Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":18,"enrollmentInfo":88,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":102,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100567463","magnetoencephalography-in-children-100567463","NCT06668519","Magnetoencephalography in Children","An Observational Study on the Clinical Application of Magnetoencephalography in Children With Neurodevelopmental Disorders","Inclusion Criteria:\n\n1. aged 1 month-18 years old (date of investigate minus date of birth)\n2. epilepsy\n3. intracranial tumors\n4. cerebrovascular diseases\n5. autism\n6. mental retardation\n7. ADHD\n8. tic disorder\n9. neuropsychiatric disorders\n\nExclusion Criteria:\n\n1.Unable to cooperate with the exam of MEG","1 Month",{"count":89,"type":21},1500,"3 Years","OBSERVATIONAL","This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.",[94,95,31,96,97,98,99,100,101],"Epilepsy","Intracranial Tumors","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","Neuropsychiatric Disorders","Tic Disorder, Childhood","Mental Retardation","Developmental Disabilities",[103,104,105],"neurodevelopmental diseases","magnetoencephalography","pediatric","2026-03-24",{"date":108,"type":47},"2026-03-25",{"date":110,"type":47},"2024-09-25",{"date":112,"type":21},"2027-12-30",{"name":114,"class":54},"Children's Hospital of Fudan University",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":4},"100623834","efficacy-and-safety-evaluation-of-remote-ischemic-adaptation--intermittent-pressure-stimulation--in-the-treatment-of-insomnia-after-stroke-100623834","NCT07401784","Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of Insomnia After Stroke","Inclusion Criteria:\n\n* Age 18-80 years old ;\n* In line with the diagnostic criteria of ischemic stroke, with reference to the ' Chinese guidelines for the diagnosis and treatment of acute ischemic stroke ' diagnosed ischemic stroke ;\n* Despite adequate sleep opportunities, patients still have difficulty in falling asleep or maintaining sleep, staying asleep at least 3 times a week for at least 3 months, which leads to pain or impaired daytime function.\n* PSQI score ≥ 6 and ISI score ≥ 8 ;\n* All research contents have been understood and informed consent has been signed.\n\nExclusion Criteria:\n\n* Insomnia before stroke ;\n* Patients with mental disorders, bipolar disorder or depression, generalized anxiety disorder and other mental disorders ;\n* Patients were pregnant or lactating women ;\n* Other reasons identified by the researchers are not suitable for patients ;","80 Years",{"count":124,"type":21},40,[67],"The incidence of post-stroke depression is high, which will affect the rehabilitation of neurological function, damage cognitive function, and increase the risk of subsequent stroke recurrence. The guidelines recommend that in addition to antiplatelet, blood pressure control, lipid-lowering and other treatments, secondary prevention of post-stroke depression should also be strengthened. Moreover, after the occurrence of post-stroke depression, methods such as medication and psychotherapy have their own limitations, such as potential adverse drug reactions and limited psychotherapy. Therefore, it is necessary to pay attention to the prevention of post-stroke depression.\n\nThe remote ischemic adaptation therapy applied in our study is a safe, non-invasive and convenient physical therapy. By transiently and repeatedly applying ischemia-reperfusion stimulation to both upper arms, it induces a systemic protective response, improves the brain 's tolerance to ischemia and hypoxia, and exerts a protective effect on multiple organs such as the brain and heart. The RIC therapeutic instrument has been national patented and has been maturely applied to the prevention and treatment of acute cerebral infarction, which can promote the rehabilitation of neurological function. In addition, it also has certain curative effect in the treatment of cerebrovascular stenosis, refractory hypertension, depression, insomnia, anxiety and so on.",[128,129,31],"Cerebral Apoplexy","Depression Anxiety Disorder",[131,132,129,31],"Remote ischemic adaptation technology","cerebral apoplexy","2026-02-03",{"date":135,"type":47},"2026-02-10",{"date":137,"type":21},"2026-01-27",{"date":112,"type":21},{"name":140,"class":54},"Second Affiliated Hospital of Nanchang University",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":115},"100583103","clinical-evaluation-of-eeg-device-for-the-triage-of-stroke-patients-in-the-ambulance-100583103","NCT06871969","Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance","Clinical Evaluation of Pre-hospital Stroke Triage Devices - Electroencephalography","CROSSROADS-EEG","Inclusion Criteria:\n\n* Suspected acute stroke as per judgement of the ambulance personnel.\n* Age 18 years or older.\n* Onset of symptoms (or last seen well) \\\u003C24 hours.\n* Written informed consent by patient or legal representative (deferred).\n\nExclusion Criteria:\n\n\\- Injuries or infections of the scalp in the area of the electrode headset placement.",{"count":150,"type":21},275,[67],"Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) strokes, but it can only be performed in specialized hospitals. Since ambulance personnel cannot determine if a patient is eligible for EVT, 54% of LVO stroke patients are initially taken to non-EVT-capable hospitals, resulting in an average delay of 1 hour in time-to-EVT in the Netherlands. To reduce this delay, it is crucial for ambulance personnel to identify potential LVO stroke patients and directly transport them to EVT-capable hospitals. Dry electrode electroencephalography (EEG) has shown high diagnostic accuracy for detecting LVO strokes, but in 32% of patients, the EEG signal quality was too poor to analyze.\n\nTo address this issue, TrianecT developed StrokePointer, a portable EEG-based triage device designed to collect and analyze EEG data in patients with suspected acute stroke. The objective of this study is to validate the effectiveness and safety of StrokePointer in detecting LVO stroke among patients with a suspected stroke in the pre-hospital setting.",[154,30,155,156,157,158,159,31],"Ischemic Stroke","Cardiovascular Diseases","Vascular Diseases","Central Nervous System Diseases","Brain Diseases","Nervous System Diseases","2025-09-30",{"date":162,"type":47},"2025-10-03",{"date":164,"type":47},"2025-07-01",{"date":166,"type":21},"2026-12",{"name":168,"class":54},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":115},"100601766","renal-denervation-after-stroke-reds-study---a-randomized-clinical-trial-of-renal-denervation-in-the-subacute-phase-of-stroke-100601766","NCT07114757","REnal Denervation After Stroke (REDs) Study - A Randomized Clinical Trial of Renal Denervation in the Subacute Phase of Stroke","REDs","Inclusion Criteria:\n\n\\- We will enroll patients (at least 18 years of age and younger than 85 years old) with subacute stroke (thus occurring 7-45 days before screening), admitted to hospital, with persistently high systolic PB (≥140 mm Hg computed as the mean of 3 repeated measurements taken within 5 minutes between 8.00am and 8.30 am on 2 consecutive days, thus totaling 6 measurements), or a non-dipper profile at ambulatory BP monitoring, despite therapy with ≥2 anti-hypertensive drugs at maximum tolerated dose. Patients should be medically stable with no severe complications such as infections, or worsening of neurological status that would require immediate and intensive medical or surgical intervention.\n\nExclusion Criteria:\n\n* ⦁ Patients with cerebral bleeding due to arteriovenous malformation or intracranial aneurysm\n\n  * Hemodynamic instability\n  * Comorbidity with life expectancy ≤ 1 year\n  * Renal artery anatomy, which prevents the procedure\n  * Reno vascular disease\n  * Vascular occlusion, which prevents the procedure\n  * Secondary hypertension\n  * Subject has known hypersensitivity or contraindication to any of the study drugs\n  * The subject is currently participating in another investigational drug or device clinical study\n  * Pregnancy or nursing\n  * Presence of other anatomic or comorbid conditions or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements or impact the scientific soundness of the clinical investigation results","84 Years",{"count":178,"type":21},108,[67],"The REnal Denervation after stroke (REDs) study is a national, multicenter, investigator-initiated randomized controlled clinical trial designed to assess the efficacy of catheter-based renal denervation (RDN) performed in the subacute phase of stroke among patients with drug-resistant hypertension. Conducted across 15 Italian centers, this pragmatic trial adopts a parallel-group design with participants randomized in a 1:1 ratio to receive either RDN using the Symplicity Spyral system or standard care. Randomization will occur via a secure online platform, and the intervention will be performed within 24 hours post-randomization, adhering to a standardized procedural protocol.\n\nThe trial targets adult patients aged 18 to 84 years who have experienced a stroke 7 to 45 days prior to enrollment and present with persistent systolic hypertension (≥140 mmHg) or a non-dipping profile on ambulatory blood pressure monitoring, despite the use of at least two antihypertensive medications at maximum tolerated doses. Following informed consent and verification of eligibility, enrolled patients will undergo baseline assessments including physical examination, laboratory testing, ECG, stroke severity and disability scoring, and quality of life evaluation.\n\nThe total duration of the REDs study is 48 months, encompassing a 24-month enrollment window and a 24-month follow-up period. Study endpoints, including 24-hour ambulatory blood pressure and secondary clinical and functional outcomes, will be evaluated at 3, 6, 9, 12, and 24 months following the intervention. These follow-up assessments will be conducted through hospital visits or teleconsultations as appropriate.\n\nThe primary efficacy endpoint is the change in mean 24-hour systolic blood pressure 12 months after randomization. Secondary endpoints include diastolic and mean arterial pressure, antihypertensive medication burden, time to blood pressure control, functional neurological scores (NIHSS, mRS), quality of life metrics, and stroke recurrence. Data collection will be managed via an electronic case report form (eCRF), and adverse events will be monitored throughout the study in line with ISO14155 and GCP standards.\n\nThis trial is supported by an unrestricted grant from Medtronic and adheres to ethical guidelines as outlined by the Declaration of Helsinki and GDPR. The REDs study aims to generate clinically relevant evidence to support the integration of RDN into secondary prevention strategies for stroke patients with resistant hypertension.",[155,31,182,183,184,30],"Arterial Hypertension","Hypertension","Renal Denervation","2025-08-04",{"date":187,"type":47},"2025-08-11",{"date":189,"type":21},"2025-09-25",{"date":191,"type":21},"2029-09-25",{"name":193,"class":54},"Centro per la Lotta Contro l'Infarto - Fondazione Onlus",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":115},"100596716","phase-4-the-analgesic-effect-of-scalp-nerve-block-using-bupivacaine-liposomes-for-postoperative-pain-relief-after-craniotomy-100596716","NCT07049094","The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy","A Multicenter, Single-blind, Randomized Controlled Study on the Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ASA I-III\n* Scheduled for elective cranial surgery\n* Informed consent from the patient or legal representative\n\nExclusion Criteria:\n\n* Preoperative Glasgow score \\\u003C 15\n* Preoperative headache with NRS ≥ 4\n* Anticipated postoperative sedation or extubation difficulties requiring mechanical ventilation\n* Inability to understand the numerical rating scale (NRS)\n* Allergies or contraindications to amide local anesthetics, opioids, or NSAIDs\n* Long-term opioid or corticosteroid treatment (\\> 2 weeks)\n* History of drug abuse in the past 2 years\n* Daily alcohol consumption exceeding 3 standard doses\n* Mental or cognitive disorders affecting perioperative assessment\n* Contraindications for nerve blocks, including infection or tumors at the puncture site, diagnosed diabetic peripheral neuropathy, or inability to cooperate\n* Severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (requiring dialysis preoperatively), or severe heart failure (METS \\\u003C 4)\n* Pregnant or breastfeeding women\n* History of craniotomy or pre-existing pathological pain conditions (e.g., migraines, trigeminal neuralgia)\n* Incisions for craniotomy extending beyond the area covered by the scalp nerve blocks\n* Participation in other clinical trials",{"count":202,"type":21},218,[24],"After undergoing craniotomy, 60% to 84% of neurosurgery patients experience moderate to severe acute pain, primarily in the first 48 hours. This pain is mostly superficial, affecting the muscles and soft tissues around the skull. Poor pain management can lead to complications such as restlessness, nausea, hypertension, increased intracranial pressure, and prolonged recovery, potentially resulting in chronic headaches.\n\nOpioids are commonly used to manage this pain but can cause significant side effects like sedation, nausea, and increased intracranial pressure, which can mask serious conditions. Non-opioid medications and scalp infiltration techniques can help but may not provide sufficient pain relief for the duration needed.\n\nCurrently, multimodal analgesia, particularly scalp nerve blocks, is advocated in neurosurgical recovery practices. These blocks are effective and simpler to perform, but the effects of long-acting local anesthetics, like bupivacaine, typically last only 24 hours. Since pain often persists longer than that, there is a need for better pain management strategies.\n\nLiposome bupivacaine is a new long-acting local anesthetic approved by the FDA, offering pain relief for up to 72 hours compared to regular bupivacaine's 8-hour duration. Its effectiveness has been confirmed in various nerve block procedures, but it has not been reported for scalp nerve blocks. This study aims to investigate whether liposome bupivacaine scalp nerve blocks can provide long-lasting postoperative pain relief, promote quicker recovery, and reduce complications in neurosurgery patients.",[206,31],"Brain Tumor Adult",[208,209],"supratentorial craniotomy","postoperative analgesia","2025-06-24",{"date":212,"type":47},"2025-07-03",{"date":214,"type":21},"2025-06-25",{"date":216,"type":21},"2027-12-31",{"name":218,"class":54},"Zhejiang University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":225,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":226,"targetDuration":228,"studyType":91,"phases":4,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":115},"100587191","multi-modality-imaging-standard-cohort-of-cerebrovascular-disease-100587191","NCT06925178","Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease","Inclusion Criteria:\n\n* Age between 18 and 80 years old;\n* Onset of symptoms within 7 days;\n* Clinical diagnosis of cerebrovascular disease (ischemic stroke or hemorrhagic stroke) confirmed by head imaging (CT or MRI);\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed with non-cerebrovascular diseases (such as central nervous system infections, epilepsy, and metabolic encephalopathy);\n* Patients with contraindications to multimodal CT or MRI, functional near-infrared imaging, or those who cannot cooperate to complete the relevant examinations;\n* Patients with a life expectancy of less than 3 months or those who cannot complete the study follow-up due to other reasons.",true,{"count":227,"type":21},800,"1 Year","The aim of this study is to establish a multi-center and multi-modality imaging standard cohort of cerebrovascular disease, analyze the potential mechanisms affecting the prognosis of cerebrovascular disease based on a variety of imaging methods, and explore potential therapeutic targets.",[31],[232,233,234,235],"stroke","progonosis","imaging","cognitive disorder","2025-04-06",{"date":238,"type":47},"2025-04-13",{"date":240,"type":47},"2025-01-01",{"date":242,"type":21},"2027-09-30",{"name":244,"class":54},"Beijing Tiantan Hospital",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":228,"maxAge":122,"enrollmentInfo":253,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":115},"100585442","application-of-qdsa-platform-in-cerebrovascular-diseases-100585442","NCT06902415","Application of QDSA Platform in Cerebrovascular Diseases","Research on the Application of Quantitative Digital Subtraction Angiography Hemodynamic Analysis Platform in Cerebrovascular Diseases","RADAR","Inclusion Criteria:\n\n1. Cerebrovascular diseases diagnosed and assessed by DSA for related risks and treatment options.\n2. The DSA acquisition protocol complies with the standard procedure.\n3. DSA images must include complete anteroposterior and lateral views.\n4. Raw data must be available in DICOM format.\n5. Image quality and pixel resolution must support data analysis.\n6. Patients must undergo regular follow-ups.\n\nExclusion Criteria:\n\n1. Cerebrovascular diseases not diagnosed or risk-assessed using DSA.\n2. Patients with DSA image quality insufficient for image analysis and processing.\n3. Severe organ diseases with an expected survival period of less than 2 years.\n4. Inability to cooperate with treatment and follow-up.\n5. Participation in other clinical trials within the past 6 months.\n6. Other conditions deemed by the investigator as unsuitable for participation in this trial.",{"count":254,"type":21},1000,"Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a novel hemodynamic assessment method with significant clinical potential. This study aims to establish a cerebrovascular disease cohort incorporating QDSA parameters to systematically validate the clinical value of this technology in preoperative evaluation and surgical planning, thereby providing evidence-based insights for optimizing diagnostic and therapeutic strategies.",[31],[31,258,259,30,260,261],"Quantitative Digital Subtraction Angiography","Hemodynamic","Death","Outcome","2025-03-24",{"date":264,"type":47},"2025-03-30",{"date":266,"type":21},"2025-04",{"date":268,"type":21},"2030-02",{"name":244,"class":54},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":225,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":115},"100575252","withdrawal-ai-based-low-dose-3d-dsa-reconstruction-100575252","NCT06769867","(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction","(Withdrawal) Validation of a Patient-Specific Generative AI-Based Low-Dose Cerebrovascular 3D-DSA Image Reconstruction Method: A Stepwise, Multicenter, Randomized Crossover Trial","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Requires 3D-DSA-guided interventional diagnosis or treatment (e.g., cerebral angiography, cerebral artery chemoembolization) and meets operational indications.\n3. Can understand the study's purpose, procedures, potential risks, and benefits, and voluntarily signs a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe heart or lung disease, such as heart failure or chronic obstructive pulmonary disease (COPD).\n2. History of high-dose radiation exams or treatments.\n3. Known allergies or severe adverse reactions to iodine contrast agents or other relevant medications.\n4. Pregnant or breastfeeding women.\n5. Severe comorbidities or chronic diseases (e.g., severe diabetes, renal insufficiency).\n6. Severe mental illness or cognitive impairment preventing understanding of the study procedures or providing informed consent.",{"count":278,"type":21},134,[67],"If the participants agree to participate in this study, the participants will undergo two scans (classic 3D-DSA and PS-3D-DSA assisted scan) to compare the imaging effects of both. After the procedure, the investigators will record the radiation exposure and collect DSA images.",[31],[283,284,285],"Cerebrovascular","AI","3D-DSA","2025-03-13",{"date":288,"type":47},"2025-03-18",{"date":290,"type":21},"2025-04-15",{"date":292,"type":21},"2025-05-31",{"name":294,"class":54},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":311,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":115},"100534642","safety-and-efficacy-of-enhanced-recovery-after-surgery-in-neurocritical-care-100534642","NCT06241482","Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care","A Randomized Controlled Clinical Study on Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care Patients","Inclusion Criteria:\n\n* Age 18-75 years old\n* Patients with moderate or severe acute traumatic brain injury or cerebrovascular disease requiring neurosurgical intensive care treatment\n* Hospitalization time ≥ 1 week\n* The guardian is able to understand and actively cooperate in completing the project\n* The guardian signs an informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing non-surgical treatment\n* Patients diagnosed as brain death within the first 24 hours after admission to NICU\n* Patients undergoing cardiopulmonary resuscitation, maintenance dialysis, end-stage tumors, and disseminated cancer\n* Patients who withdraw treatment during hospitalization or are discharged automatically\n* Patients who underwent unplanned secondary surgery during the research process\n* Individuals who cannot be followed up during the research process","75 Years",{"count":304,"type":21},80,[67],"Enhanced recovery after surgery (ERAS) is a strategy of perioperative management aimed to accelerate the rehabilitation of patients through various optimized perioperative managements as well as ongoing adherence to a patient-focused, multidisciplinary, and multimodal approach. Alleviating the injury and stress caused by surgery or disease is the core principle of ERAS, which has been shown to reduce complication rates after surgery, promote patient recovery, decrease hospital length of stay and reduce costs. ERAS has been widely applied in many surgical perioperative fields, and it has achieved remarkable effects. However, there are few applications of ERAS in neurosurgery, especially in clinical trials of neurocritical care patients.\n\nTherefore, the investigators attempt to conduct the study of ERAS in neurosurgical intensive patients using a series of optimized perioperative managements that have been verified to be effective by evidence-based medicine, and to evaluate the safety and effectiveness of ERAS in neurocritical care. The aim of this study is to explore the most suitable ERAS protocols to accelerate the postoperative rehabilitation process of neurocritical care patients, and to provide more evidence-based medicine for the effectiveness and safety of ERAS in neurosurgery.",[308,309,31,310],"Neurocritical Care","Traumatic Brain Injury","Moderate or Severe Coma",[308,309,31],"2025-03-03",{"date":314,"type":47},"2025-03-04",{"date":316,"type":47},"2024-10-15",{"date":318,"type":21},"2027-04-30",{"name":320,"class":54},"Shanghai 6th People's Hospital",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":329,"targetDuration":87,"studyType":91,"phases":4,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":115},"100582145","national-database-of-the-virtual-institute-of-cerebrovascular-diseases-100582145","NCT06859502","National Database of the Virtual Institute of Cerebrovascular Diseases","\"Registro Dati Nazionale Dell'Istituto Virtuale Delle Malattie Cerebrovascolari\" \"National Database of the Virtual Institute of Cerebrovascular Diseases\"","BIG-MENTI","Inclusion Criteria:\n\n* Diagnosis of cerebrovascular pathology defined according to the 1990 NINDS special report2 as \"all disorders in which an area of the brain is transiently or permanently affected by ischemia or bleeding and\u002For in which one or more of the blood vessels of the brain are primarily altered by a pathological process,\" falling under the following International Classification of Diseases, 9th revision (ICD-9) codes: ICD-9 430-438;\n* Informed consent provided by the patient or the patient's legal representative in the case of incapacitation, or by the parents\u002Fguardians in the case of minor subjects.\n\nExclusion Criteria:\n\n* The patient, his or her legal representative in the case of incapacitation, or his or her parents\u002Fguardians in the case of minor subjects irrefutably express the will to leave the study;\n* Onset of cerebrovascular disease before January 1, 2016.",{"count":330,"type":21},312800,"The overall objective of the study is to identify prognostic predictors of cerebrovascular disease during various stages of the cerebrovascular disease itself, namely: hospitalization at the acute care facility, residential hospitalization at neurorehabilitation facilities, outpatient follow-up visits, and day hospital admissions at the various facilities. The aim is to obtain data on those factors that can influence the prognosis, thus the clinical outcome, of patients with cerebrovascular disease.\n\nCerebrovascular diseases are defined by the World Health Organization (WHO) as \"all those disorders in which there is an area of the brain transiently or permanently affected by ischemia or bleeding or in which one or more cerebral blood vessels are primarily affected in a pathological process, or a combination of the two conditions mentioned above.\" These diseases include a wide range of conditions, of which ischemic stroke and cerebral hemorrhage are the most common. Given the high overall frequency of these diseases and, consequently, the high social and economic cost of them on the population, it is essential to recognize as soon as possible those factors capable of predicting the time course of patients affected, as you are, by these diseases, also with a view to identifying strategies to improve the prognosis of patients for whom an unfavorable outcome is predicted. In addition, given the high prevalence of cerebrovascular disease, it is necessary that an extremely large patient population be enrolled, and thus an enormous amount of data be collected, in order for meaningful results to be obtained.\n\nThe primary objective of this study is, in fact, to collect a large amount of clinical data, i.e., to establish a national data registry, obtained from the records of patients with cerebrovascular diseases that began after January 1, 2016, in order to be able to identify and define the subtypes of each cerebrovascular disease associated with poor prognosis. The secondary objectives are to identify clinical, neurophysiological, radiological, and biomarker data that are able to predict the clinical course of cerebrovascular disease over time and to identify prognostic scores obtained from the combination of the variables first indicated. With this study, we also aim to identify those clinical, radiological, and neurophysiological data that are able to help the clinician in the early differential diagnosis of these diseases and that are able to predict the occurrence of spontaneous or procedure-related complications and the successful outcome of treatment. Finally, we aim to identify those clinical, radiological, and neurophysiological variables that are able to predict a good outcome of rehabilitation performed as a result of the onset of cerebrovascular disease.",[31],"2025-02-28",{"date":335,"type":47},"2025-03-05",{"date":337,"type":47},"2024-09-10",{"date":339,"type":21},"2054-04-01",{"name":341,"class":54},"Fondazione Don Carlo Gnocchi Onlus",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":350,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":359,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":373},"100515753","phase-4-comparison-of-clopidogrel-based-antiplatelet-therapy-versus-warfarin-as-secondary-prevention-strategy-for-antiphospholipid-syndrome-related-stroke-100515753","NCT05995600","Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE","Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)","APS-STROKE","Inclusion Criteria:\n\n* Age 19 years or older\n* History of ischemic stroke (cerebral infarction, transient ischemic attack, or retinal arterial ischemic event)\n* Patients who meet the laboratory diagnostic criteria for antiphospholipid syndrome (APS)\n* Patients or guardians who agree to the study protocol and sign with informed consent\n\nExclusion Criteria:\n\n* Patients with high-risk antiphospholipid antibody profile (triple positivity; persistent high-titers exceeding 80 U\u002FmL of anti-cardiolipin or anti-β2 glycoprotein I antibodies)\n* Systemic lupus erythematous\n* Patients unable to discontinue previously taken anticoagulants or antiplatelet agents (e.g., atrial fibrillation, valvular heart disease, or a history of percutaneous coronary intervention)\n* Women who are pregnant, breastfeeding, or intending to become pregnant during the study period\n* Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion","19 Years",{"count":352,"type":21},200,[24],"Antiphospholipid syndrome (APS) has a close association with ischemic stroke; however, the optimal treatment strategy for APS-related stroke has yet to be established. The clinical guidelines suggest using warfarin for APS-related stroke, but these suggestions are largely based on retrospective studies from the 1990s and expert opinion, rather than high-quality clinical trials. Moreover, the evidence on the role of antiplatelet drugs other than aspirin (e.g., clopidogrel) in APS-related stroke is particularly limited. Considering the relatively young age of patients with APS and the high clinical burden of using warfarin, it is necessary to verify whether warfarin is essential. Thus, the investigators aim to compare clopidogrel-based antiplatelet therapy and warfarin as a secondary preventive medication for patients with APS-related stroke. APS-STROKE is an exploratory, multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult patients with definite APS who have a history of ischemic stroke will be included. Patients with high-risk APS (triple positivity or persistently high titers of anti-cardiolipin or anti-β2-glycoprotein I antibodies), systemic lupus erythematous, or indications for continued antiplatelet or anticoagulant therapy will be excluded. Eligible patients will be 1:1 randomized to receive clopidogrel-based antiplatelet therapy or warfarin. Patients assigned to the clopidogrel-based antiplatelet therapy group will be permitted to use additional antiplatelet drugs other than clopidogrel at the investigator's discretion. The primary outcome is a composite of any death, major adverse cardiovascular events, systemic thromboembolic events, and major bleeding during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal secondary prevention strategy for APS-related stroke.",[356,154,357,31,155,358],"Antiphospholipid Syndrome","Transient Ischemic Attack","Major Bleed",[360,361,362,363],"Antiphospholipid syndrome","Ischemic stroke","Secondary prevention","Thrombosis","2024-10-13",{"date":366,"type":47},"2024-10-16",{"date":368,"type":47},"2024-02-20",{"date":370,"type":21},"2029-03",{"name":372,"class":54},"Seoul National University Hospital",32,{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":382,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":385,"conditions":386,"keywords":390,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":115},"100559719","primary-individualized-evaluation-of-cardiovascular-events-in-patients-with-diabetes-mellitus-using-hemotag-100559719","NCT06567795","PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG","Prospective, Multi-center, Longitudinal, Study for PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG","PRIZETAG","Inclusion Criteria:\n\n1. Adult patients older than 40 years of age.\n2. Diagnosis of Type 2 Diabetes Mellitus (insulin dependent or non-insulin dependent) for at least 5 years.\n3. Diagnosis of Cardiovascular Disease (Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease, etc…) --OR--\n\n   Have one (1) of the following concomitant medical diagnoses:\n   1. Diabetic Retinopathy (proliferative or non-proliferative)\n   2. Diabetic Nephropathy (eGFR \\<60 mL\u002Fmin\u002F1.73m2 and\u002For urine albumin\u002Fcreatinine ratio ≥30 mg\u002Fg)\n   3. Diabetic Neuropathy\n   4. Elevated High-sensitivity C-reactive protein (hs-CRP) --AND--\n\n      Have a history of two (2) or more of the following:\n   5. Diagnosis of Hypertension for at least 6 months or more (treated or untreated)\n   6. Hypercholesterolemia (LDL-C \\>100 mg\u002FdL)\n   7. Obesity (Body Mass Index (BMI) ≥ 27 for men or ≥ 22 for women)\n   8. History of Smoking\n4. Willingness to undergo HEMOTAG evaluation.\n5. Willingness to undergo Standard of Care visits\u002Fassessments and NT-pro BNP lab evaluations.\n6. Willingness to conduct at-home HEMOTAG evaluations at least three days per week within a 30-day time period after the completion of the Baseline Visit, after the 6 month visit and following discharge from any hospitalizations due to a cardiac events during the 12 month study period.\n7. Willingness to receive and return shipping of the HEMOTAG KIT at each time point as required by the protocol\n8. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Terminal condition with life expectancy less than 12 months as determined by investigator.\n2. Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment.\n3. Illness\u002F Condition which may be aggravated or cause significant discomfort to the patient by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes).\n4. Participant enrolled in another interventional study (observational or registries are not excluded).\n5. Prisoners and wards of the state.\n6. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator\\'s assessment.\n7. Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)\n8. Inability to provide informed consent (Must speak English).\n9. Women who are pregnant or are planning to become pregnant during the study.\n10. Women of childbearing potential who are unwilling or unable to comply with contraception measures.","40 Years",{"count":384,"type":21},189,"To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.",[387,155,388,31,389],"Diabetes Mellitus Type 2","Coronary Artery Disease","Peripheral Artery Disease",[391,155,388],"Diabetes Mellitus","2024-08-21",{"date":394,"type":47},"2024-08-23",{"date":396,"type":47},"2024-03-14",{"date":398,"type":21},"2027-03-18",{"name":400,"class":401},"Aventusoft, LLC.","INDUSTRY",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":4},"100550885","improvement-of-medical-quality-and-outcomes-through-intelligent-management-and-decision-system-of-cerebrovascular-diseases-based-on-hospital-information-system-100550885","NCT06452888","Improvement of Medical Quality and Outcomes Through Intelligent Management and Decision System of Cerebrovascular Diseases Based on Hospital Information System","Improvement of Medical Quality and Outcomes Through Intelligent Management and Decision System of Cerebrovascular Diseases Based on Hospital Information System - A Multicenter, Open-label, Cluster-Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18.\n* Diagnosed with ischemic stroke confirmed by magnetic resonance imaging (MRI) or brain computed tomography (CT).\n* Within 7 days from onset of symptoms.\n* With a NIHSS score of ≥2 at admission (limb score ≥1).\n* With a prestroke mRS score of 0-1.\n* Admission from the emergency department or outpatient service.\n* Voluntary informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of other cerebrovascular diseases (cerebral hemorrhage, subarachnoid hemorrhage, cerebral venous sinus thrombosis, etc.).\n* Diagnosis of non-cerebrovascular disease (central nervous system infection, epilepsy, metabolic encephalopathy, etc.).\n* Ischemic stroke with negative diffusion weighted imaging (DWI).\n* Being tested for interventions such as drugs or instruments.\n* Pregnancy or 6 weeks postpartum.\n* With a life expectancy of less than 3 months or who were unable to complete the study follow-up for other reasons.",{"count":410,"type":21},3540,[67],"This study applied a cerebrovascular disease organizational management and decision system based on hospital information system, aiming to verify the effect of intervention and management after stroke on improving the functional outcomes of acute ischemic cerebrovascular disease through a cluster randomized controlled study.",[31],[154,415,416,417,418,419],"Medical Quality","Clinical Complication","Clinical decision Support System","Electronic Health Record","Artificial Intelligence","2024-06-06",{"date":422,"type":47},"2024-06-11",{"date":424,"type":21},"2024-07-01",{"date":426,"type":21},"2026-02-01",{"name":244,"class":54},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":325,"officialTitle":325,"acronym":327,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":433,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":115},"100510381","national-database-of-the-virtual-institute-of-cerebrovascular-diseases-100510381","NCT05925699","Inclusion Criteria:\n\n* Diagnosis of cerebrovascular pathology defined according to the NINDS special report of 1990 as \"all disorders in which there is an area of the brain transiently or permanently affected by ischemia or bleeding and\u002For in which one or more blood vessels of the brain are mainly altered by a pathological process\", falling within the following codes of the International Classification of Diseases, 9th revision (ICD-9): ICD-9 430-438;\n* Informed consent provided by the patient or his legal representative in the case of mental incapacity or by the parents\u002Fguardians in the case of minors.\n\nExclusion Criteria:\n\n* The patient, his legal representative in the case of mental incapacity or his parents\u002Fguardians in the case of minors clearly state their will to leave the study;\n* Onset of cerebrovascular disease before January 1, 2016.",{"count":434,"type":21},285600,"The primary aim of the study is to develop a national registry of cerebrovascular diseases in order to define the subtypes of these diseases associated with a worse prognosis. Secondly, the study aims to find clinical, radiological, and biological markers capable tof predicting the outcome of cerebrovascular diseases and the onset of complications related to therapeutic procedures, and to calculate predictive prognostic scores composed of multiple variables.\n\nEach participating center will collect clinical, radiological, and biological data from the medical records of the study participants. Patients included in the study will not undergo any additional medical procedures to those of normal clinical practice.",[31],"2023-07-12",{"date":439,"type":47},"2023-07-13",{"date":441,"type":21},"2023-09-01",{"date":443,"type":21},"2052-09-01",{"name":445,"class":54},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":453,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":115},"100402812","phase-2-egb-761-in-the-syndrome-of-mci-with-concomitant-cvd-100402812","NCT04525144","EGb 761 in the Syndrome of MCI With Concomitant CVD","Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)","Inclusion Criteria:\n\n* Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria\n* Patients who have a Global Clinical Dementia Rating Score of 0.5\n* Patients aged 45 to 85 years at study entry\n* Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators\n* Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans\n* Patients who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information\u002FSummary of Product Characteristics (SmPC) should be observed.","45 Years","85 Years",{"count":278,"type":21},[457],"PHASE2","EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.",[460,31],"Mild Cognitive Impairment","2022-11-14",{"date":463,"type":47},"2022-11-17",{"date":465,"type":47},"2020-10-26",{"date":467,"type":21},"2026-11",{"name":469,"class":54},"National Neuroscience Institute",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":115},"100396541","assess-the-risk-of-cerebrovascular-disease-100396541","NCT04443439","Assess the Risk of Cerebrovascular Disease","Head and Neck CTA Combined With Multimodal MRI to Assess the Risk of Cerebrovascular Disease","Inclusion Criteria:\n\n1. Mild stenosis group: CTA suggested carotid stenosis \\\u003C 30%;\n2. Moderate stenosis group: CTA suggested carotid stenosis of 30-69%;\n3. Severe stenosis group: CTA indicated carotid stenosis ≥70%;\n\nExclusion Criteria:\n\n1. dementia, MMSE score \\\u003C 21;\n2. previous carotid stenosis related neurological symptoms or transient ischemic attack;\n3. other craniocerebral lesions, such as craniocerebral trauma, tumor, inflammation, and complications of great vessels (cerebral infarction or cerebral malacia);\n4. contraindications for MRI examination;\n5. recent use of psychoactive drugs or hormones.",{"count":478,"type":21},100,"Intracranial artery stenosis is an important cause of ischemic stroke, but the degree of intracranial artery stenosis is not completely matched with the symptoms of ischemic stroke. Asymptomatic carotid stenosis (ACS) refers to does not appear related neurological symptoms of carotid stenosis and stroke or transient ischemic attack of carotid stenosis, did not happen cerebrovascular events such as stroke, but there have been a different degree of cognitive impairment, be badly in need of development of noninvasive imaging methods, objective evaluation of the ACS group cognitive impairment, and predict the ACS risk of ischemic stroke. Therefore, this topic proposed comprehensive cognitive assessment, CTA, double modal MRI techniques, clinical and biochemical indicator detection, mathematical modeling and statistical analysis techniques, assess the ACS group and normal person the cognitive ability, the difference of NVC and local perfusion, and follow-up ACS crowd of ischemic stroke and other cardiovascular events, discuss ACS and cognitive impairment, the correlation of NVC and local perfusion abnormalities, screening of radiographic predictor of ischemic stroke, and in the follow-up of ACS population in testing the sensitivity of the series of indicators and specific degrees.",[31],"2022-10-23",{"date":483,"type":47},"2022-10-25",{"date":485,"type":47},"2020-10-09",{"date":487,"type":21},"2026-12-01",{"name":489,"class":54},"Tang-Du Hospital",{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":225,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":115},"100461369","brain-diseases-on-70t-magnetic-resonance-imaging-100461369","NCT05287750","Brain Diseases on 7.0T Magnetic Resonance Imaging","Inclusion Criteria:\n\n* Age≥18 and ≤80\n* Having brain diseases (eg: brain tumor, cerebrovascular diseases)\n* Having no contraindications against MRI or intravenous contrast agent administration\n* Clinically stable\n\nExclusion Criteria:\n\n* Age\\\u003C18 or \\>80\n* Pregnancy and other contraindication to MRI scan\n* Informed consent not obtained",{"count":352,"type":21},[67],"This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.",[500,501,31],"Brain Tumor","MRI",[503,504,501,505],"Brain tumor","Cerebrovascular disease","Ultra high field","2022-03-15",{"date":508,"type":47},"2022-03-18",{"date":510,"type":47},"2022-01-01",{"date":512,"type":21},"2026-09-01",{"name":514,"class":54},"Chinese PLA General Hospital",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":522,"targetDuration":524,"studyType":91,"phases":4,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":115},"100437976","diabetes-complications-and-the-risk-of-cardiovascular-and-cerebrovascular-diseases-100437976","NCT04983277","Diabetes Complications and the Risk of Cardiovascular and Cerebrovascular Diseases","Study of Diabetes Mellitus and Its Complications and the Risk of Cardiovascular and Cerebrovascular Diseases","Inclusion Criteria:\n\n* Diabetic symptoms with: plasma glucose level at any time ≥11.1mmol\u002F L (200mg\u002F dL), or Fasting plasma glucose level ≥7.0mmol\u002F L (126mg\u002F dL), or plasma glucose level ≥11.1mmol\u002F L (200ng\u002F dL) for 2 h in OGTT test, or HbA1c ≥6.5%; Or those without typical symptoms should repeated the tests in another day.\n* Han Chinese.\n* Willingness to participate.\n\nExclusion Criteria:\n\n* Secondary diabetes.\n* Participants in other clinical trials.",{"count":523,"type":21},3000,"1 Week","This study is intended to include 3000 diabetic patients in our hospital to collect complete medical history data, comprehensively improve the screening of diabetic complications and cardiovascular and cerebrovascular risk assessment.",[527,155,31],"Diabetes Complications","2021-07-27",{"date":530,"type":47},"2021-07-30",{"date":532,"type":21},"2021-07",{"date":534,"type":21},"2030-12",{"name":536,"class":54},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]